Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jennal Johnson"'
Autor:
Howard Wolpert, Eric S. Meadows, Stephanie Edwards, Xuanyao He, Wenjie Wang, Jennal Johnson, David Price, Jiat-Ling Poon, William H. Polonsky
Publikováno v:
Diabetes Technology & Therapeutics
Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf5ba04ddb62663930ea2e257d5da67
http://europepmc.org/articles/PMC8783630
http://europepmc.org/articles/PMC8783630
Autor:
David Rodbard, Liza L. Ilag, Kelly Ellinor, Ludi Fan, Thomas Blevins, Jennal Johnson, Trang T. Ly, Dana Sindelar, Wendy Lane
Publikováno v:
Diabetes Technology & Therapeutics. 23:51-58
Background: The EValuating U-500R Infusion Versus Injection in Type 2 Diabetes Mellitus (VIVID) study compared two methods of U-500R insulin delivery, continuous subcutaneous insulin infusion (CSII...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8befafbb8a78adcca425d4544bf84464
https://doi.org/10.1089/dia.2020.0030
https://doi.org/10.1089/dia.2020.0030
Publikováno v:
Diabetes, Obesity & Metabolism
Human regular U‐500 insulin (U‐500R) provides both basal and prandial coverage to people with diabetes. As part of the VIVID study, we studied patient‐reported outcomes (PRO) of U‐500R delivered by multiple daily injections (MDI, n = 211) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e35d7df9fc88c3c88d0d08323ff8f7c
https://doi.org/10.1111/dom.14191
https://doi.org/10.1111/dom.14191
Autor:
Anuj Bhargava, Shuyu Zhang, Liza L. Ilag, Howard Zisser, Jennal Johnson, Ludi Fan, James Malone, Trang T. Ly, George Grunberger
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the safety and efficacy of U500‐R delivered by a novel, specifically designed U500‐R insulin pump with U‐500R delivered by multiple daily injections (MDI). Methods The phase 3 VIVID study randomized people with type 2 diabetes to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d11d6ca8fa5d2bef198eedc6a920c1
http://europepmc.org/articles/PMC7065168
http://europepmc.org/articles/PMC7065168
Autor:
Xuanyao He, Jennal Johnson, Zhenxiang Zhao, Stefanie L. Painter, Christopher M. Whaley, Wei Lu, Jennifer B. Bollyky, Eric S. Meadows, Jennifer L. Schneider
Publikováno v:
Journal of Medical Economics. 22:869-877
Aims: Many new mobile technologies are available to assist people in managing chronic conditions, but data on the association between the use of these technologies and medical spending remains limited. As the available digital technology offerings to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfce6139e34b9d08137ec8c63bb747f
https://doi.org/10.1080/13696998.2019.1609483
https://doi.org/10.1080/13696998.2019.1609483
Autor:
Derek J. Leishman, Alex Nguyen, Jeffrey A. Jackson, Linda Morrow, Helle Linnebjerg, Jennal Johnson, Xiaosu Ma, Shuyu Zhang, Randy Prescilla, Liza L. Ilag, Charles Benson, Elizabeth Smith Labell
Publikováno v:
J Diabetes Sci Technol
Introduction: Human regular U-500 insulin (U-500R) is approved for subcutaneous (SC) injection in patients with diabetes requiring >200 units/day of insulin. Here, pharmacokinetic and pharmacodynamic (PK/PD) profiles following U-500R administered by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02365d41a67570dad48bec1e0e1ce7e1
https://pubmed.ncbi.nlm.nih.gov/33242998
https://pubmed.ncbi.nlm.nih.gov/33242998
Autor:
William H. Polonsky, Howard Wolpert, Jennal Johnson, Wenjie Wang, Eric S. Meadows, Stephanie S. Edwards, Xuanyao He
Publikováno v:
Diabetes. 69
Connected insulin pens have potential utility as diagnostic tools to objectively assess MBDs and their impact on glycemic outcomes. This cross-sectional study enrolled 68 people with T1D or insulin-using T2D (A1C ≥ 8%, ≥ 3 insulin boluses/day rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5d381025dcbeb949615e0a8ecc30510
https://doi.org/10.2337/db20-375-p
https://doi.org/10.2337/db20-375-p
Publikováno v:
Diabetes Technology & Therapeutics. 19:483-490
The purpose of this prospective, model-based simulation approach was to evaluate the impact of various rapid-acting mealtime insulin dose-titration algorithms on glycemic control (hemoglobin A1c [HbA1c]).Seven stepwise, glucose-driven insulin dose-ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af3e133229e3db4045a443b0ac7e61e
https://doi.org/10.1089/dia.2016.0361
https://doi.org/10.1089/dia.2016.0361
Autor:
David Price, William H. Polonsky, Stephanie Edwards, Christi Y. Kao, Eric S. Meadows, Jiat Ling Poon, Xuanyao He, Wolpert Howard, Jennal Johnson
Publikováno v:
Diabetes. 68
When people with diabetes (PwD) are introduced to real-time continuous glucose monitoring (rtCGM), they may still struggle to meet glycemic targets, as highlighted by the T1D Exchange. We assessed missed bolus doses (MBD) in relation to psychosocial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2233de36e1d2d152f0521d24cf69b077
https://doi.org/10.2337/db19-83-lb
https://doi.org/10.2337/db19-83-lb
Publikováno v:
The Diabetes Educator. 42:271-280
Purpose Patient-centric methods to support diabetes management are important to overcome barriers associated with initiating mealtime insulin. This article describes the subject-driven titration tools implemented in the AUTONOMY trial to initiate and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d16dfd2b054932053821e5361afe0f
https://doi.org/10.1177/0145721716642297
https://doi.org/10.1177/0145721716642297